Predict your next investment

Elpiscience Biopharmaceuticals company logo
HEALTHCARE | Drug Development
elpiscience.com

See what CB Insights has to offer

Founded Year

2017

Stage

Series C | Alive

Total Raised

$260M

Last Raised

$105M | 8 mos ago

About Elpiscience Biopharmaceuticals

Elpiscience Biopharmaceuticals is an immunology-driven company that develops immunotherapies to fight cancer.

Elpiscience Biopharmaceuticals Headquarter Location

987 Cailun Rd., Pudong 3F

Shanghai, Shanghai, 201203,

China

+86 21 50651310

Latest Elpiscience Biopharmaceuticals News

Elpiscience Announces First Patient Dosed in US Phase I Clinical Trial of Anti-CD39 Monoclonal Antibody ES002 for Treatment of Advanced Solid Tumors

Jan 20, 2022

January 20, 2022 08:30 AM Eastern Standard Time SHANGHAI & SUZHOU, China & GERMANTOWN, Md.--( BUSINESS WIRE )--Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer immunotherapies, today announced that the first patient has been dosed in a U.S. multi-center, Phase I clinical trial, evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ES002, the company’s proprietary anti-CD39 monoclonal antibody (mAb), that is being developed for the treatment of advanced solid tumors ( NCT05075564 ). Elpiscience received U.S. Food and Drug Administration (FDA) IND clearance for ES002 in September 2021. “We are very pleased to see ES002 enter clinical trial testing in the United States,” said Steve Chin, CMO of Elpiscience. “This is an important milestone for Elpiscience to develop innovative and differentiated cancer immunotherapies. We look forward to announcing additional clinical milestones throughout 2022 as Elpiscience expands its pipeline with a steadfast commitment to advance One World Class Molecule into the Clinic Each Year.” ES002 has demonstrated highly potent single-agent anti-tumor activity showing significant reduction in tumor size and weight in in-vivo pharmacology studies . About ES002: ES002 is an anti-CD39 mAb designed to promote anti-tumor immunity. CD39 is a key enzyme regulating the production of adenosine, a critical immune suppressor. By blocking CD39 function, ES002 also stabilizes pro-inflammatory extracellular ATP (eATP) and restores anti-tumor immunity within the tumor microenvironment. ES002 demonstrated highly potent single-agent anti-tumor activity in in-vivo pharmacology studies. About Elpiscience: Elpiscience is a clinical stage biopharmaceutical company focused on innovating and developing next-generation immunotherapy to benefit cancer patients worldwide. The company has a robust pipeline of globally innovative molecules, covering wide range of targets in immuno-oncology. It has four molecules in clinical trials (ES002, ES101, ES102, and ES104), and endeavors to clinically advance at least one innovative molecule a year. Founded and managed by a team of biopharma industry leaders, Elpiscience is backed by renowned investors including, Lilly Asia Ventures, Hillhouse Capital, Hyfinity Investments, Greater Bay Area Homeland Development Fund, CDH, DYEE Capital and Cormorant Asset Management. Learn more at elpiscience.com

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Elpiscience Biopharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Elpiscience Biopharmaceuticals is included in 3 Expert Collections, including Biopharma Tech.

B

Biopharma Tech

5,239 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Elpiscience Biopharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Elpiscience Biopharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.